bluebird bio

News

FDA sets November review date for J&J's multiple myeloma CAR...

Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), narrowing the lead for Bristol-Myers Squibb and bluebi

Views & Analysis

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

New Cell & Gene Therapy Collective seeks to boost UK adoptio...

The UK has been a global leader in introducing cell and gene therapies that can potentially transform the lives of patients with debilitating diseases – but there are still many barriers to

News

CHMP backs bluebird bio's gene therapy for rare disease ALD

US biotech bluebird bio has had a challenging time in the last few months, so a recommendation for EU approval of its gene therapy for adrenoleukodystrophy (ALD) will give it a lift.

News

bluebird bio announces long-term data from CALD gene therapy

bluebird bio has announced new clinical trial data from its gene therapy for patients with cerebral adrenoleukodystrophy (CALD), including long-term follow-up data.

News

bluebird seeks gene therapy trial restart after cancer scare

bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was "

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Zynteglo halt re-ignites viral vector safety concerns; analy...

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors

FDA sets November review date for J&J's multiple myeloma CAR...

New Cell & Gene Therapy Collective seeks to boost UK adoptio...

CHMP backs bluebird bio's gene therapy for rare disease ALD

bluebird bio announces long-term data from CALD gene therapy

bluebird seeks gene therapy trial restart after cancer scare

Zynteglo halt re-ignites viral vector safety concerns; analy...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

bluebird bio

Editor's Picks